Revamped Modus Switches To Sepsis, Septic Shock For Sevuparin
Swedish Biotech Had Unsuccessfully Targeted Sickle Cell Disease
Executive Summary
After disappointment in sickle cell anemia, Modus Therapeutics will now develop its lead asset sevuparin as a treatment for sepsis and septic shock and plans a public listing in Sweden to fund the new strategy, its CEO tells Scrip.